Portal de Periódicos da CAPES

Eculizumab in Atypical Hemolytic–Uremic Syndrome

2013; Massachusetts Medical Society; Volume: 369; Issue: 14 Linguagem: Inglês

10.1056/nejmc1308826

1533-4406

Troels Ring,

Renal Diseases and Glomerulopathies

CI], 0.57 to 0.83) for the first 21 days, 1.00 (95% CI, 0.57 to 1.76) for 22 to 60 days, and 0.38 (95% CI, 0.18 to 0.82) for 61 to 90 days.We also await results of trials such as POINT and TARDIS for confirmation of these results in non-Chinese populations.We agree with Jeong that there may be important differences according to the patients' ethnicity and environment that limit the generalizability of our results, and we await the results of future clinical trials.